NeuroPace (NPCE) News Today $12.66 -5.02 (-28.39%) Closing price 04:00 PM EasternExtended Trading$12.76 +0.10 (+0.75%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NPCE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period NeuroPace, Inc.: NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS StudyMay 27 at 4:49 PM | finanznachrichten.deNeuroPace stock sinks following clinical study resultsMay 27 at 4:49 PM | za.investing.comNeuroPace Shares Plunge After Mixed Clinical Trial ResultsMay 27 at 4:49 PM | msn.comNeuroPace falls after setback in trial for neuromodulation systemMay 27 at 4:49 PM | msn.comWhy Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?May 27 at 12:48 PM | benzinga.comNeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS StudyMay 27 at 8:00 AM | globenewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Northern Trust CorpNorthern Trust Corp boosted its holdings in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 15.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 184,847 shares of the company's sMay 27 at 3:02 AM | marketbeat.comPoint72 Asset Management L.P. Invests $369,000 in NeuroPace, Inc. (NASDAQ:NPCE)Point72 Asset Management L.P. acquired a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 32,943 shares of the company's stock, valued at approximately $369,000. Point72 Asset ManagMay 26 at 4:06 AM | marketbeat.comNeuroPace (NASDAQ:NPCE) Hits New 52-Week High - What's Next?NeuroPace (NASDAQ:NPCE) Hits New 52-Week High - What's Next?May 24 at 5:40 AM | marketbeat.com100,095 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Acquired by Jane Street Group LLCJane Street Group LLC bought a new stake in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 100,095 shares of the company's stock, valued at approxiMay 24 at 3:19 AM | marketbeat.comCantor Fitzgerald maintains Overweight on NeuroPace stockMay 21, 2025 | uk.investing.comJacobs Levy Equity Management Inc. Acquires Shares of 57,096 NeuroPace, Inc. (NASDAQ:NPCE)Jacobs Levy Equity Management Inc. acquired a new stake in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 57,096 shares of the company's stock, valued at approximatMay 20, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 168,136 SharesMay 17, 2025 | insidertrades.comNeuroPace's (NPCE) "Overweight" Rating Reiterated at Cantor FitzgeraldMay 17, 2025 | americanbankingnews.comNeuroPace (NASDAQ:NPCE) Sets New 52-Week High Following Analyst UpgradeMay 17, 2025 | americanbankingnews.comNeuroPace (NASDAQ:NPCE) Reaches New 1-Year High After Analyst UpgradeNeuroPace (NASDAQ:NPCE) Sets New 1-Year High on Analyst UpgradeMay 17, 2025 | marketbeat.comNeuroPace, Inc.'s (NASDAQ:NPCE) large institutional owners must be happy as stock continues to impress, up 29% over the past weekMay 15, 2025 | finance.yahoo.comNeuroPace, Inc. (NPCE) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comNeuroPace, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 13, 2025 | seekingalpha.comNeuroPace Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comNeuroPace (NPCE) to Release Quarterly Earnings on WednesdayNeuroPace (NASDAQ:NPCE) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-neuropace-inc-stock/)May 9, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by JPMorgan Chase & Co.JPMorgan Chase & Co. lifted its stake in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 440.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 64,826 shares of the company's stock after purchasing an additionaMay 2, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Holdings Decreased by Nantahala Capital Management LLCNantahala Capital Management LLC trimmed its position in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 7.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 562,073 shares of the company's stock after selling 45,817 shares dApril 30, 2025 | marketbeat.comWalleye Capital LLC Acquires New Stake in NeuroPace, Inc. (NASDAQ:NPCE)Walleye Capital LLC bought a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 28,547 shares of the company's stock, valued at approximately $319,000. Walleye Capital LLC owned 0.10% ofApril 27, 2025 | marketbeat.comNeuroPace Stock Short Interest Report | NASDAQ:NPCE | BenzingaApril 20, 2025 | benzinga.comNeuroPace, Inc. (NASDAQ:NPCE) Short Interest UpdateNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 449,600 shares, a growth of 45.8% from the March 15th total of 308,300 shares. Approximately 2.0% of the company's shares are short sold. Based on an average daily volume of 242,200 shares, the short-interest ratio is currently 1.9 days.April 20, 2025 | marketbeat.comNeuroPace, Inc.: NeuroPace Provides Update on Tariff StatusApril 17, 2025 | finanznachrichten.deNeuroPace expects minimal impact from tariffsApril 15, 2025 | markets.businessinsider.comNeuroPace Provides Update on Tariff StatusApril 14, 2025 | globenewswire.comNeuroPace, Inc.: NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingApril 8, 2025 | finanznachrichten.deNeuroPace announces data from long-term post-approval study of RNS SystemApril 8, 2025 | markets.businessinsider.comNeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingApril 8, 2025 | globenewswire.comQ1 Earnings Estimate for NeuroPace Issued By Leerink PartnrsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for NeuroPace in a research note issued to investors on Thursday, April 3rd. Leerink Partnrs analyst M. Kratky expects that the company will post earnings per shareApril 8, 2025 | marketbeat.comWells Fargo Remains a Buy on NeuroPace (NPCE)April 5, 2025 | markets.businessinsider.comNeuroPace (NPCE) Receives a Buy from Lake StreetApril 4, 2025 | markets.businessinsider.comNeuroPace to terminate distribution relationship for Seeg productsApril 3, 2025 | markets.businessinsider.comNeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual MeetingApril 3, 2025 | globenewswire.comNeuroPace Announces Refocusing of Product PortfolioApril 2, 2025 | globenewswire.comNeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% - What's Next?NeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% - Here's WhyMarch 30, 2025 | marketbeat.comNeuroPace to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | globenewswire.comNeuroPace at attractive entry point, remains best idea, says Cantor FitzgeraldMarch 19, 2025 | markets.businessinsider.comNeuroPace’s SWOT analysis: stock poised for growth amid expanding marketMarch 14, 2025 | investing.comCantor Fitzgerald Predicts Higher Earnings for NeuroPaceNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of NeuroPace in a report issued on Wednesday, March 5th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.54) for the year, up fromMarch 8, 2025 | marketbeat.comNeuroPace (NASDAQ:NPCE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst SaysCantor Fitzgerald lifted their target price on NeuroPace from $19.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday.March 6, 2025 | marketbeat.comNeuroPace (NASDAQ:NPCE) Issues Earnings Results, Beats Expectations By $0.07 EPSNeuroPace (NASDAQ:NPCE - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.March 5, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | insidermonkey.comNeuroPace reports Q4 EPS (18c), consensus (22c)March 4, 2025 | markets.businessinsider.comNeuroPace sees FY25 revenue $92M-$96M, consensus $92.96MMarch 4, 2025 | markets.businessinsider.comNeuroPace, Inc. (NPCE) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comNeuroPace Inc.: Q4 Earnings SnapshotMarch 4, 2025 | finance.yahoo.com Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address NPCE Media Mentions By Week NPCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NPCE News Sentiment▼0.701.02▲Average Medical News Sentiment NPCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NPCE Articles This Week▼123▲NPCE Articles Average Week Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enovis News NovoCure News LeMaitre Vascular News CONMED News Warby Parker News National Vision News Tandem Diabetes Care News Liquidia News Cadre News Artivion News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NPCE) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NPCE Stock Free NPCE Stock Alerts